Revvity Surges 7.8%, Analysts Chase the Print

RVTY jumped 7.8% on November 3 to close at $163.48, the same day its put/call ratio hit its most defensive reading in months, and analysts rushed to lift targets the morning after.

The speed of the analyst response is striking. RBC Capital raised its target from $135 to $172 on November 4, maintaining Sector Perform. Evercore ISI moved its target from $165 to $180 on the same morning, keeping its Outperform rating. Both moves came after the stock had already cleared most prior targets. The consensus mean sits at $149.87, now firmly below where the stock is trading. TD Cowen had already moved to $175 in mid-October from $130, and William Blair initiated at Outperform in early October. The cumulative picture is a Street scrambling to catch up with a stock that has run 61.9% year to date. With the consensus target now a discount to the current price, valuation support from analyst models has effectively evaporated, and the debate shifts to whether the results on November 5 justify the premium. The trailing P/E runs at 28x, with EV/EBITDA at 21.3x, both up meaningfully on the month.

Short positioning reinforces that covering, not conviction, has driven recent movement. Short interest dropped 10.6% over the past week to 5.1% of free float, the lowest level in at least a year. That weekly decline runs about 1.6 standard deviations below the company's typical weekly move, meaning shorts are covering at an unusually fast pace. The borrow market is entirely relaxed: cost to borrow is 0.46%, and availability has expanded to 676% of outstanding short interest, up 45% on the week. The 52-week trough for availability was 156%, so the current reading is nowhere near stressed. The ORTEX short score has fallen from 50.4 on October 23 to 43.7 on November 3, moving away from the neutral midpoint as bearish positioning unwinds. Nothing here looks like a squeeze; it looks like shorts stepping aside ahead of the print.

Options positioning cuts the other way. The put/call ratio rose to 0.89 on November 3, nearly 2.8 standard deviations above its 20-day average of 0.61. That is the most protection-heavy reading in recent months, and it arrived on the same day as the 7.8% surge, a combination that suggests some participants bought downside insurance into strength rather than chasing it. The 52-week range for the PCR is 0.08 to 10.05, so the absolute level is not extreme, but the speed of the move in a single session is what stands out.

Among peers, RVTY's 1.0% weekly gain stands out against a broadly negative backdrop. ILMN fell 14.8% on the week and FTRE dropped 14.2%. SHC lost 13.3%. WAT and TMO fell 1.8% and gained 0.8% respectively, the two most range-bound names in the group. The life sciences tools sector absorbed heavy selling this reporting season while RVTY moved in the opposite direction, a divergence that makes the November 5 result more watched than a typical quarterly print.

T. Rowe Price remains the dominant holder at just over 21% of shares, and its two affiliated entities together hold roughly 21% based on the most recent 13G filings. EdgePoint Investment Group has built to 7.4% and Janus Henderson holds 6.6%, both passive 13G filers. No 13D activist is on the register. The concentration of ownership at T. Rowe Price means any shift in that position would carry outsized weight on the stock. All 13D/G stakes are as last disclosed around the 5% threshold and may not reflect current holdings.

The November 5 earnings release is the immediate focus. The specific question is whether Immunodiagnostics ex-China and Life Sciences Solutions, together roughly 70% of revenue, show evidence of the step-up toward the 6% to 8% growth corridor that the bull case requires, or whether the two segments that have driven the year's re-rating deliver growth that the now-premium multiple cannot absorb.